#biotech
biotech
222,493 visninger
334 debatterer
Populært
Seneste
Parabilis raises 670M in record biotech IPO, signaling renewed risk appetite in healthcare innovation
🧬 Parabilis Medicines began trading on Nasdaq under the ticker PBLS after selling 33.5 million shares at 20 USD per share, raising around 670 million USD through its IPO. The size of the deal makes it one of the most notable biotech listings of 2026.
🏛️ The key point is not only the capital raised, but also the fact that the offering was upsized while the biotech IPO market remains selective. This suggests investors are still willing to back companies with differentiated technology, clear clinical programs and strong long-term potential.
🤝 Regeneron also joined a concurrent private placement of around 75 million USD and had already entered a strategic collaboration with Parabilis in May. The involvement of a major pharmaceutical name adds more attention to Helicon, Parabilis’ peptide platform designed to reach intracellular targets that traditional drugs often struggle to address.
🔬 The new funding will support the development of zolucatetide, the company’s lead program targeting desmoid tumors and other cancers linked to the Wnt/β-catenin pathway. Parabilis aims to move this program closer to Phase 3 development in 2027.
⚖️ Despite the positive IPO narrative, Parabilis remains a clinical-stage biotech company with meaningful trial risk. After the initial listing phase, clinical data, pipeline execution and institutional demand will matter more than the headline IPO size.
#Biotech $BTC $BNB $HNT
🧬 Parabilis Medicines began trading on Nasdaq under the ticker PBLS after selling 33.5 million shares at 20 USD per share, raising around 670 million USD through its IPO. The size of the deal makes it one of the most notable biotech listings of 2026.
🏛️ The key point is not only the capital raised, but also the fact that the offering was upsized while the biotech IPO market remains selective. This suggests investors are still willing to back companies with differentiated technology, clear clinical programs and strong long-term potential.
🤝 Regeneron also joined a concurrent private placement of around 75 million USD and had already entered a strategic collaboration with Parabilis in May. The involvement of a major pharmaceutical name adds more attention to Helicon, Parabilis’ peptide platform designed to reach intracellular targets that traditional drugs often struggle to address.
🔬 The new funding will support the development of zolucatetide, the company’s lead program targeting desmoid tumors and other cancers linked to the Wnt/β-catenin pathway. Parabilis aims to move this program closer to Phase 3 development in 2027.
⚖️ Despite the positive IPO narrative, Parabilis remains a clinical-stage biotech company with meaningful trial risk. After the initial listing phase, clinical data, pipeline execution and institutional demand will matter more than the headline IPO size.
#Biotech $BTC $BNB $HNT
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
$BIO is gaining some solid attention today.The token has been showing decent volume and steady buying interest. With its focus on decentralized biotechnology, longevity, and health data, $BIO is becoming one of the more unique and promising projects in the BioTech x Crypto space.Many traders are now watching if it can break its recent resistance and move higher.Are you holding $BIO or planning to enter on this move?
Drop your thoughts #BIO #BioTech
Drop your thoughts #BIO #BioTech
$BIO
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
The biggest wealth transfer in crypto won't come from finance. It will come from biology.
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
#modernarisesover12% 🚀 $MRNAon
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
AngelOfCrypto_-:
👍👍👍👍👍
Moderna ($MRNAon ) Skyrockets Over 12%! Biotech Rally Sparks Market Interest
The traditional stock market is witnessing massive movements as Moderna ($MRNAon ) surges nearly 13%, hitting a fresh 52-week high of $67.78!
The explosive rally comes right after Moderna hosted its highly anticipated Science Day event, where it showcased a powerful pipeline of upcoming mRNA advancements—including oncology (cancer therapies) and a unanimous FDA advisory committee nod for its seasonal flu vaccine ($mRNA-1010).
While tech and AI chip stocks faced heavy volatility and pulled back, capital rotated aggressively into the healthcare and biotech sectors.
💡 Key Takeaways for Crypto & Macro Traders:
× The Biotech Pivot: Major institutional interest is returning to biotech and mRNA technology breakthroughs.
× Liquidity Rotation: When tech giants take a breather, macro liquidity frequently shifts to defensive and innovation-heavy sectors like healthcare.
× Crypto Correlation: Sharp stock market movements often influence overall high-risk asset sentiment, keeping crypto traders on alert for macro volatility.
Are you watching traditional equity markets for clues on the next big crypto move, or focusing purely on $BTC and $ETH ? Let's discuss in the comments! 👇
#writetoearn #ModernaRisesOver12% #Write2Earn #Biotech #MacroNews
The traditional stock market is witnessing massive movements as Moderna ($MRNAon ) surges nearly 13%, hitting a fresh 52-week high of $67.78!
The explosive rally comes right after Moderna hosted its highly anticipated Science Day event, where it showcased a powerful pipeline of upcoming mRNA advancements—including oncology (cancer therapies) and a unanimous FDA advisory committee nod for its seasonal flu vaccine ($mRNA-1010).
While tech and AI chip stocks faced heavy volatility and pulled back, capital rotated aggressively into the healthcare and biotech sectors.
💡 Key Takeaways for Crypto & Macro Traders:
× The Biotech Pivot: Major institutional interest is returning to biotech and mRNA technology breakthroughs.
× Liquidity Rotation: When tech giants take a breather, macro liquidity frequently shifts to defensive and innovation-heavy sectors like healthcare.
× Crypto Correlation: Sharp stock market movements often influence overall high-risk asset sentiment, keeping crypto traders on alert for macro volatility.
Are you watching traditional equity markets for clues on the next big crypto move, or focusing purely on $BTC and $ETH ? Let's discuss in the comments! 👇
#writetoearn #ModernaRisesOver12% #Write2Earn #Biotech #MacroNews
#ModernaRisesOver12% Moderna ($MRNA) Surges Over 12%, Hitting 52-Week Highs on Pipeline Breakthroughs 🚀
Moderna is proving there is life—and massive growth—well beyond COVID-19 vaccines. The stock surged over 12% on Friday, hitting a 52-week high of $67.78, fueled by a highly successful "Science Day" investor presentation.
Investors are rallying behind strong diversification milestones, including:
Unanimous FDA Advisory Support: A clean 9-0 vote favoring their investigational seasonal flu vaccine (mRNA-1010) ahead of its August PDUFA date.
Oncology Breakthroughs: Exciting pipeline updates regarding cancer antigen therapies (like mRNA-4194 for Lynch Syndrome).
Autoimmune Progress: Advancing the mRNA-6007 CAR-T program into early development for Lupus.
With Wall Street targets shifting upwards (Piper Sandler raised its target to $77), Moderna is successfully reshaping its narrative into a diversified mRNA powerhouse.
#Biotech #StockMarket #MrNaveed #Investing
Moderna is proving there is life—and massive growth—well beyond COVID-19 vaccines. The stock surged over 12% on Friday, hitting a 52-week high of $67.78, fueled by a highly successful "Science Day" investor presentation.
Investors are rallying behind strong diversification milestones, including:
Unanimous FDA Advisory Support: A clean 9-0 vote favoring their investigational seasonal flu vaccine (mRNA-1010) ahead of its August PDUFA date.
Oncology Breakthroughs: Exciting pipeline updates regarding cancer antigen therapies (like mRNA-4194 for Lynch Syndrome).
Autoimmune Progress: Advancing the mRNA-6007 CAR-T program into early development for Lupus.
With Wall Street targets shifting upwards (Piper Sandler raised its target to $77), Moderna is successfully reshaping its narrative into a diversified mRNA powerhouse.
#Biotech #StockMarket #MrNaveed #Investing
MRNAonAlpha
MRNAUS+0,88%
🚀 MODERNA SURGES OVER 12%! Hits New 52-Week High 🧬
Moderna ($MRNAon ) stock just experienced a massive rally, jumping over 12% to reach a 52-week high of $67.78.
💥 What Triggered the Rally?
Pipeline Progress & Price Target Hikes: Following Moderna's recent Science Day presentation highlighting research on cancer antigen therapies, Piper Sandler raised its price target on the stock from $69 to $77 and maintained an Overweight rating.
FDA Panel Backing: The FDA's vaccine advisory panel recently voted unanimously to recommend approval for Moderna's proposed mRNA flu vaccine (mRNA-1010) for adults aged 50 to 64, with support for accelerated approval for those 65 and older.
International Sales Boost: International demand for Moderna's COVID-19 vaccine has risen, which offset domestic sales declines and boosted first-quarter revenue beyond Wall Street expectations.
Options Frenzy: Options trading activity surged significantly, with 121,257 contracts traded. The most active contract was the June 18, 2026, $65 call.
📊 The Macro Picture:
The biotech giant has engineered a stunning turnaround in 2026. After hitting a 52-week low of $22.28, the stock has skyrocketed, logging a 145.18% gain over the past year and a 103% return year-to-date.
#ModernaRisesOver12% #moderna #stockmarket #Biotech #TradingNews
$VELVET
$BEAT
Moderna ($MRNAon ) stock just experienced a massive rally, jumping over 12% to reach a 52-week high of $67.78.
💥 What Triggered the Rally?
Pipeline Progress & Price Target Hikes: Following Moderna's recent Science Day presentation highlighting research on cancer antigen therapies, Piper Sandler raised its price target on the stock from $69 to $77 and maintained an Overweight rating.
FDA Panel Backing: The FDA's vaccine advisory panel recently voted unanimously to recommend approval for Moderna's proposed mRNA flu vaccine (mRNA-1010) for adults aged 50 to 64, with support for accelerated approval for those 65 and older.
International Sales Boost: International demand for Moderna's COVID-19 vaccine has risen, which offset domestic sales declines and boosted first-quarter revenue beyond Wall Street expectations.
Options Frenzy: Options trading activity surged significantly, with 121,257 contracts traded. The most active contract was the June 18, 2026, $65 call.
📊 The Macro Picture:
The biotech giant has engineered a stunning turnaround in 2026. After hitting a 52-week low of $22.28, the stock has skyrocketed, logging a 145.18% gain over the past year and a 103% return year-to-date.
#ModernaRisesOver12% #moderna #stockmarket #Biotech #TradingNews
$VELVET
$BEAT
Verificeret
#modernarisesover12%
Moderna $MRNA.US
on Fire: 14% Surge & Pipeline Breakthroughs! Here is the Market Reality: 👇
The Reality Behind the Rally:
Pipeline Progress:
The surge follows a wave of optimism regarding Moderna's mRNA research, including a unanimous positive vote from an FDA advisory committee for its seasonal influenza vaccine ($mRNA-1010$) for adults 50 and older.
Institutional Confidence: Piper Sandler recently raised its price target for $MRNA.US from $69 to $77, citing significant research advancements in cancer antigen therapies and autoimmune disease treatments like the $mRNA-6007$ CAR-T program.
Global Reach:
While domestic COVID-19 vaccine sales have softened, Moderna’s international demand remains a strong revenue driver that continues to offset U.S. market declines.
The Macro Crypto Takeaway:
When biotech heavyweights demonstrate that mRNA technology can diversify far beyond respiratory vaccines—moving into oncology and autoimmune sectors—it signals a massive shift in how the market values "decentralized" scientific innovation and high-tech biological platforms.
For the Web3 ecosystem, this focus on complex, high-throughput data and intellectual property infrastructure mirrors the institutional appetite for specialized, scalable networks. As Moderna proves the long-term viability of its platform, liquidity naturally favors assets that provide the foundational compute and verification layers for such deep-tech advancements. Stay defensive with your leverage and track the institutional volume.
Primary institutional base layers and high-utility assets to monitor:
$BTC
| $ETH | $SOL | $BNB
#Biotech #NASDAQ #CryptoTradin #MacroEconomics
Moderna $MRNA.US
on Fire: 14% Surge & Pipeline Breakthroughs! Here is the Market Reality: 👇
The Reality Behind the Rally:
Pipeline Progress:
The surge follows a wave of optimism regarding Moderna's mRNA research, including a unanimous positive vote from an FDA advisory committee for its seasonal influenza vaccine ($mRNA-1010$) for adults 50 and older.
Institutional Confidence: Piper Sandler recently raised its price target for $MRNA.US from $69 to $77, citing significant research advancements in cancer antigen therapies and autoimmune disease treatments like the $mRNA-6007$ CAR-T program.
Global Reach:
While domestic COVID-19 vaccine sales have softened, Moderna’s international demand remains a strong revenue driver that continues to offset U.S. market declines.
The Macro Crypto Takeaway:
When biotech heavyweights demonstrate that mRNA technology can diversify far beyond respiratory vaccines—moving into oncology and autoimmune sectors—it signals a massive shift in how the market values "decentralized" scientific innovation and high-tech biological platforms.
For the Web3 ecosystem, this focus on complex, high-throughput data and intellectual property infrastructure mirrors the institutional appetite for specialized, scalable networks. As Moderna proves the long-term viability of its platform, liquidity naturally favors assets that provide the foundational compute and verification layers for such deep-tech advancements. Stay defensive with your leverage and track the institutional volume.
Primary institutional base layers and high-utility assets to monitor:
$BTC
| $ETH | $SOL | $BNB
#Biotech #NASDAQ #CryptoTradin #MacroEconomics
هل تخيلت يوماً أن يتحول البحث العلمي من شهور من العمل المختبري إلى مجرد أيام؟ 🧬
أطلقت شركة NVIDIA مؤخراً أداة BioNeMo Agent Toolkit، وهي نقلة نوعية حقيقية في عالم الذكاء الاصطناعي الحيوي. هذه الحزمة ليست مجرد أدوات، بل هي "عقل" يساعد الباحثين والوكلاء الذكاء الاصطناعي على التعاون لإجراء تجارب حسابية معقدة، وتحليل النتائج، واقتراح الخطوات التالية بدقة متناهية.
إليك لماذا هذا الخبر يهمنا:
تسريع الاكتشاف: تحويل مهام البحث التي كانت تستغرق شهوراً إلى أيام.
دقة عالية: تمكين الوكلاء الذكاء الاصطناعي من التفكير والتعليل بشكل أعمق بناءً على نتائج البحث.
التعاون: تسهيل العمل بين المختبرات والأنظمة الذكية بشكل غير مسبوق.
هذا التطور يعزز مكانة $NVDA ليس فقط كعملاق للرقائق، بل كمهندس للبنية التحتية العلمية للمستقبل. الذكاء الاصطناعي يخرج من نطاق الشات بوتس ليغير حياة البشر فعلياً.
هل تعتقد أن دمج الذكاء الاصطناعي في الأبحاث الحيوية سيغير خريطة صناعة الأدوية في السنوات القليلة القادمة؟ شاركني رأيك في التعليقات! 👇
$NVDAB
$NVDAon
#Nvidia #AI #BioTech #الذكاء_الاصطناعي #تكنولوجيا #ابتكار #BioNeMo
أطلقت شركة NVIDIA مؤخراً أداة BioNeMo Agent Toolkit، وهي نقلة نوعية حقيقية في عالم الذكاء الاصطناعي الحيوي. هذه الحزمة ليست مجرد أدوات، بل هي "عقل" يساعد الباحثين والوكلاء الذكاء الاصطناعي على التعاون لإجراء تجارب حسابية معقدة، وتحليل النتائج، واقتراح الخطوات التالية بدقة متناهية.
إليك لماذا هذا الخبر يهمنا:
تسريع الاكتشاف: تحويل مهام البحث التي كانت تستغرق شهوراً إلى أيام.
دقة عالية: تمكين الوكلاء الذكاء الاصطناعي من التفكير والتعليل بشكل أعمق بناءً على نتائج البحث.
التعاون: تسهيل العمل بين المختبرات والأنظمة الذكية بشكل غير مسبوق.
هذا التطور يعزز مكانة $NVDA ليس فقط كعملاق للرقائق، بل كمهندس للبنية التحتية العلمية للمستقبل. الذكاء الاصطناعي يخرج من نطاق الشات بوتس ليغير حياة البشر فعلياً.
هل تعتقد أن دمج الذكاء الاصطناعي في الأبحاث الحيوية سيغير خريطة صناعة الأدوية في السنوات القليلة القادمة؟ شاركني رأيك في التعليقات! 👇
$NVDAB
$NVDAon
#Nvidia #AI #BioTech #الذكاء_الاصطناعي #تكنولوجيا #ابتكار #BioNeMo
Delvist sandt
🚨 $LAB _USDT Quick Analysis @ $9.91
LAB is formulating a major breakout, compounding by +41.27% to sit just under the psychological $10 milestone. The DeSci (Decentralized Science) narrative is reaching a boiling point as laboratory-on-chain fundraising models gain mainstream tracking.
LAB provides a decentralized marketplace for IP-NFTs and biotech fractional ownership. Speculation is mounting over an impending partnership with global research institutions to tokenize medical patents, drawing high-net-worth liquidity into the token.
TA Snapshot
Immediate Resistance: Facing extreme sell pressure at $10.00. A breakout here initiates a blue-sky regime.
Support Base: Local support securely locked at $8.50.
Momentum: Nuclear volume profiles. RSI sits at 75, suggesting extreme strength but elevated risk for late-stage chasers.
DYOR | NFA
#Labs #DeSci #Biotech #LABUSDT #TrendingTopic $LAB @EliteDailySignals
📹 We Live-stream a Bitcoin Footprint Chart every US (NY) session, it runs from ⏰️ 9h30 am EST/ (14h30 GMT) Set an Alarm, be disciplined! 🇺🇲🇬🇧🇩🇪
Move with the market - move with us!
LAB is formulating a major breakout, compounding by +41.27% to sit just under the psychological $10 milestone. The DeSci (Decentralized Science) narrative is reaching a boiling point as laboratory-on-chain fundraising models gain mainstream tracking.
LAB provides a decentralized marketplace for IP-NFTs and biotech fractional ownership. Speculation is mounting over an impending partnership with global research institutions to tokenize medical patents, drawing high-net-worth liquidity into the token.
TA Snapshot
Immediate Resistance: Facing extreme sell pressure at $10.00. A breakout here initiates a blue-sky regime.
Support Base: Local support securely locked at $8.50.
Momentum: Nuclear volume profiles. RSI sits at 75, suggesting extreme strength but elevated risk for late-stage chasers.
DYOR | NFA
#Labs #DeSci #Biotech #LABUSDT #TrendingTopic $LAB @EliteDailySignals
📹 We Live-stream a Bitcoin Footprint Chart every US (NY) session, it runs from ⏰️ 9h30 am EST/ (14h30 GMT) Set an Alarm, be disciplined! 🇺🇲🇬🇧🇩🇪
Move with the market - move with us!
🚨 ¡TENSIÓN BIOTECNOLÓGICA! 🇨🇳 WUXI APPTEC RECHAZA ACUSACIÓN DEL PENTÁGONO TRAS SER LISTADA COMO "EMPRESA MILITAR" 🇺🇸
¡Fricción geopolítica de última hora! 💥 El gigante de la biotecnología WuXi AppTec acaba de emitir un comunicado urgente declarando que el Departamento de Defensa de EE. UU. cometió un grave error al incluirla en su lista negra oficial actualizada de "empresas militares chinas" bajo la Sección 1260H. 🏛️⚠️
📌 Lo que debes saber en un vistazo:
Falsa Alarma o Estrategia: La compañía de origen chino desmintió rotundamente cualquier vínculo con el ejército de su país, afirmando que su operación es exclusivamente civil y enfocada en la salud. 🔬🛡️
Acciones Legales Inmediatas: WuXi AppTec anunció a través de informes de Ming Pao que impugnará formalmente la decisión y tomará todas las medidas legales necesarias para corregir esta designación errónea. 📈💼
Impacto en Wall Street: El reingreso a la lista del Pentágono golpea de inmediato la reputación corporativa del grupo y activa alertas automáticas en las cadenas de suministro farmacéuticas globales. 📉💸
La disputa regulatoria abre un nuevo frente en la batalla tecnológica entre Washington y Pekín, sacudiendo las carteras de los inversores institucionales en el sector de la biotecnología. ¿Lograrán revocar la medida o aumentará la presión? ⏳🕒
#WuXiAppTec #Geopolitica #Biotech #StocksNews #BinanceSquare
👇 Monitorea la acción del precio en vivo y los muros de órdenes aquí abajo:
$BTC
¡Fricción geopolítica de última hora! 💥 El gigante de la biotecnología WuXi AppTec acaba de emitir un comunicado urgente declarando que el Departamento de Defensa de EE. UU. cometió un grave error al incluirla en su lista negra oficial actualizada de "empresas militares chinas" bajo la Sección 1260H. 🏛️⚠️
📌 Lo que debes saber en un vistazo:
Falsa Alarma o Estrategia: La compañía de origen chino desmintió rotundamente cualquier vínculo con el ejército de su país, afirmando que su operación es exclusivamente civil y enfocada en la salud. 🔬🛡️
Acciones Legales Inmediatas: WuXi AppTec anunció a través de informes de Ming Pao que impugnará formalmente la decisión y tomará todas las medidas legales necesarias para corregir esta designación errónea. 📈💼
Impacto en Wall Street: El reingreso a la lista del Pentágono golpea de inmediato la reputación corporativa del grupo y activa alertas automáticas en las cadenas de suministro farmacéuticas globales. 📉💸
La disputa regulatoria abre un nuevo frente en la batalla tecnológica entre Washington y Pekín, sacudiendo las carteras de los inversores institucionales en el sector de la biotecnología. ¿Lograrán revocar la medida o aumentará la presión? ⏳🕒
#WuXiAppTec #Geopolitica #Biotech #StocksNews #BinanceSquare
👇 Monitorea la acción del precio en vivo y los muros de órdenes aquí abajo:
$BTC
$COIN FOUNDER’S LONGEVITY BET RAISES $435M 🧬
NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round led by Founders Fund, with participation from Thrive Capital, Greenoaks, and Quiet Capital. The company plans to move its first age-reprogramming drug into human trials next year, marking a notable institutional capital flow into biotech-adjacent innovation.
For crypto markets, the direct impact on $COIN is limited, but the raise reinforces Armstrong’s broader positioning beyond digital assets. Serious traders should separate founder-related narrative momentum from core exchange fundamentals, liquidity trends, and regulatory risk.
Not financial advice. Manage your risk.
#CryptoNews #Coinbase #Biotech #VentureCapital #BinanceSquare
⚡
NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round led by Founders Fund, with participation from Thrive Capital, Greenoaks, and Quiet Capital. The company plans to move its first age-reprogramming drug into human trials next year, marking a notable institutional capital flow into biotech-adjacent innovation.
For crypto markets, the direct impact on $COIN is limited, but the raise reinforces Armstrong’s broader positioning beyond digital assets. Serious traders should separate founder-related narrative momentum from core exchange fundamentals, liquidity trends, and regulatory risk.
Not financial advice. Manage your risk.
#CryptoNews #Coinbase #Biotech #VentureCapital #BinanceSquare
⚡
$BIO Showing Signs of Life – Recovery Mode
➤ $BIO is trading at $0.03287 (+3.95%) following a prolonged downtrend.
➤ While the broader trend remains bearish, early signs of a potential bottoming formation are beginning to emerge.
════════════════════════════
◆ Technical Analysis
➤ Price has declined steadily from the $0.047 high before finding support around $0.0285 – $0.0290.
➤ Recent bullish candles indicate a short-term recovery attempt.
➤ Price has moved above nearby moving averages.
➤ Rising upside volume suggests improving buyer interest.
➤ Positive sentiment from recent listing-related developments may be contributing to momentum.
════════════════════════════
◆ Scenario Analysis
① Bullish Case
✔︎ Sustained move above $0.0335
✔︎ Continued volume expansion
➜ Potential targets: $0.035 → $0.037
② Bearish Case
✔︎ Failure to hold $0.032
✔︎ Breakdown below $0.031
➜ Possible decline toward $0.028
════════════════════════════
◆ Key Levels
➤ Resistance
✔︎ R1: $0.0335
✔︎ R2: $0.0350
➤ Support
✔︎ S1: $0.0315
✔︎ S2: $0.0288
════════════════════════════
◆ Outlook
➤ BIO is attempting to establish a recovery structure.
➜ The key test is whether buyers can successfully turn $0.0335 into support.
➜ Higher-timeframe sellers remain active, making risk management especially important.
════════════════════════════
#BIO #BİO #Biotech
➤ $BIO is trading at $0.03287 (+3.95%) following a prolonged downtrend.
➤ While the broader trend remains bearish, early signs of a potential bottoming formation are beginning to emerge.
════════════════════════════
◆ Technical Analysis
➤ Price has declined steadily from the $0.047 high before finding support around $0.0285 – $0.0290.
➤ Recent bullish candles indicate a short-term recovery attempt.
➤ Price has moved above nearby moving averages.
➤ Rising upside volume suggests improving buyer interest.
➤ Positive sentiment from recent listing-related developments may be contributing to momentum.
════════════════════════════
◆ Scenario Analysis
① Bullish Case
✔︎ Sustained move above $0.0335
✔︎ Continued volume expansion
➜ Potential targets: $0.035 → $0.037
② Bearish Case
✔︎ Failure to hold $0.032
✔︎ Breakdown below $0.031
➜ Possible decline toward $0.028
════════════════════════════
◆ Key Levels
➤ Resistance
✔︎ R1: $0.0335
✔︎ R2: $0.0350
➤ Support
✔︎ S1: $0.0315
✔︎ S2: $0.0288
════════════════════════════
◆ Outlook
➤ BIO is attempting to establish a recovery structure.
➜ The key test is whether buyers can successfully turn $0.0335 into support.
➜ Higher-timeframe sellers remain active, making risk management especially important.
════════════════════════════
#BIO #BİO #Biotech
Verificeret
$BIOUSDT Quick Analysis @ $0.0308
Bio Protocol ($BIO ) synthesizes a baseline with a +2.67% increase over the past day. The decentralized science (DeSci) financial network is carving out a stable valuation floor as its "BioXP" staking upgrade and "BioAgents" AI development platform drive ecosystem alignment.
Bio Protocol serves as a decentralized funding layer for early-stage biotechnology, leveraging specialized tokenized networks to fund longevity and synthetic biology research. The asset is a pure fundamental play on the emerging DeSci vertical, trading on long-term project launch mechanics rather than purely speculative liquidity cycles.
TA Snapshot
Immediate Resistance: Needs to break cleanly past the $0.0325 horizontal resistance to confirm a structure shift.
Support Base: Built a strong defensive base at $0.0290; the 50-day moving average acts as local support.
Momentum: RSI is perfectly resting in the neutral zone (~50), though a slight daily bullish divergence suggests selling pressure has plateaued.
The range is tightly wound. Watch for a volume expansion above $0.0315 to confirm an immediate breakout attempt toward the $0.040 macro target.
DYOR | NFA
#BIOProtocol #BIO #DeSci #Biotech #biousdt $BIO @BIO Protocol @EliteDailySignals
📹 We Live-stream a Bitcoin Footprint Chart every US (NY) session, it runs from ⏰️ 9h30 am EST/ (14h30 GMT) Set an Alarm, be disciplined! 🇺🇲🇬🇧🇩🇪
Move with the market - move with us!
Bio Protocol ($BIO ) synthesizes a baseline with a +2.67% increase over the past day. The decentralized science (DeSci) financial network is carving out a stable valuation floor as its "BioXP" staking upgrade and "BioAgents" AI development platform drive ecosystem alignment.
Bio Protocol serves as a decentralized funding layer for early-stage biotechnology, leveraging specialized tokenized networks to fund longevity and synthetic biology research. The asset is a pure fundamental play on the emerging DeSci vertical, trading on long-term project launch mechanics rather than purely speculative liquidity cycles.
TA Snapshot
Immediate Resistance: Needs to break cleanly past the $0.0325 horizontal resistance to confirm a structure shift.
Support Base: Built a strong defensive base at $0.0290; the 50-day moving average acts as local support.
Momentum: RSI is perfectly resting in the neutral zone (~50), though a slight daily bullish divergence suggests selling pressure has plateaued.
The range is tightly wound. Watch for a volume expansion above $0.0315 to confirm an immediate breakout attempt toward the $0.040 macro target.
DYOR | NFA
#BIOProtocol #BIO #DeSci #Biotech #biousdt $BIO @BIO Protocol @EliteDailySignals
📹 We Live-stream a Bitcoin Footprint Chart every US (NY) session, it runs from ⏰️ 9h30 am EST/ (14h30 GMT) Set an Alarm, be disciplined! 🇺🇲🇬🇧🇩🇪
Move with the market - move with us!
$BIO
– Bio Protocol
BIO–BIO–0.0428 ▲ +33.33% #BioProtocol
Bio Protocol is today's biggest gainer with a 33% surge. BIO is a DeSci (Decentralized Science) management and liquidity protocol that accelerates biotech funding by enabling collective investment in tokenized scientific IP. The DeSci sector is gaining significant attention as investors look for the next narrative. Resistance at 0.045.Supportat0.045.Supportat0.040. Momentum is building.
#BIO #BioProtocol #DeSci #DecentralizedScience #Biotech
– Bio Protocol
BIO–BIO–0.0428 ▲ +33.33% #BioProtocol
Bio Protocol is today's biggest gainer with a 33% surge. BIO is a DeSci (Decentralized Science) management and liquidity protocol that accelerates biotech funding by enabling collective investment in tokenized scientific IP. The DeSci sector is gaining significant attention as investors look for the next narrative. Resistance at 0.045.Supportat0.045.Supportat0.040. Momentum is building.
#BIO #BioProtocol #DeSci #DecentralizedScience #Biotech
Log ind for at udforske mere indhold